Biovitrum and Symphogen Report Positive Clinical Results in Novel Rh-immunization Prevention Project
This part of the first clinical study investigated the ability of Sym001 to clear RhD-positive red blood cells given intravenously to 24 RhD-negative healthy males. Positive control was the plasma-derived product Rhophylac®, given to 12 subjects. The preliminary results demonstrate that the recombinant human polyclonal antibody product is able to clear RhD-positive blood cells at five days after dosing in a dose dependent manner.
Biovitrum and Symphogen are now planning for the next step of the clinical programme which should lead to a decision to initiate phase III studies in the intended label population, namely Rh-negative mothers carrying an Rh-positive fetus
"Sym001 is the first ever recombinant human polyclonal antibody product to have entered human clinical trials and this red blood cell challenge study is an important step in the further development of Sym001", said Kirsten Drejer, CEO of Symphogen. "Symphogen's antibody technology platform offers the opportunity to generate compositions of recombinant human polyclonal antibodies as well as single monoclonal antibodies which opens an exciting avenue for development of antibody therapeutics addressing unmet medical needs."
Other news from the department research and development
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous